Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment

/PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that...

Related Keywords

United States ,Hong Kong ,American ,Joe Dorame ,Robert Blum ,Joe Diaz ,Scott Grindrod ,Anatoly Dritschilo ,Lytham Partners ,Georgetown University ,Prnewswire Shuttle Pharmaceuticals Holdings Inc ,Shuttle Pharmaceuticals Holdings Inc ,Nasdaq ,American Cancer Society ,Shuttle Pharmaceuticals ,Pharmaceuticals Holdings ,Chief Executive Officer ,Laboratory Director ,Histone Deacetylase Inhibitors ,Human Disease ,Function Molecules ,Histone Deacetylase Inhibition ,Ataxia Telangiectasia Mutated Activation ,Hong Kong Patent ,Medical Center ,